AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases

by Rai Ajit K. Srivastava, Stephen L. Pinkosky, Sergey Filippov, Jeffrey C. Hanselman, Clay T. Cramer, Roger S. Newton
Published 2012-12-01

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

by Sergey Filippov, Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Jeffrey C. Hanselman, Clay T. Cramer, Rai Ajit K. Srivastava, Timothy R. Hurley, Cheryl D. Bradshaw, Mark A. Spahr, Roger S. Newton
Published 2013-08-01

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

by Stephen L. Pinkosky, Roger S. Newton, Emily A. Day, Rebecca J. Ford, Sarka Lhotak, Richard C. Austin, Carolyn M. Birch, Brennan K. Smith, Sergey Filippov, Pieter H.E. Groot, Gregory R. Steinberg, Narendra D. Lalwani
Published 2016-11-01

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism[S]

by Stephen L. Pinkosky, Sergey Filippov, Rai Ajit K. Srivastava, Jeffrey C. Hanselman, Cheryl D. Bradshaw, Timothy R. Hurley, Clay T. Cramer, Mark A. Spahr, Ashley F. Brant, Jacob L. Houghton, Chris Baker, Mark Naples, Khosrow Adeli, Roger S. Newton
Published 2013-01-01